Table 3.
Effect of selected mitocan combinations on acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML) cell lines.
| Cell line (leukemia type) | Maximal synergya, mean ± SEM | |||
|---|---|---|---|---|
| IACS/VIN* | RT/2-DG** | CCCP/DAS* | ABT-199/LND** | |
| CCRF-CEM (ALL) | 30.8 ± 8.2 | 84.9 ± 1.8 | 21.5 ± 2.7 | 21.1 ± 3.5 |
| MOLT-4 (ALL) | 9.0 ± 2.0 | 62.8 ± 10.9 | 8.1 ± 1.3 | 44.1 ± 5.0 |
| K-562 (CML) | 32.7 ± 7.1 | 53.2 ± 14.4 | 53.1 ± 3.9 | 17.4 ± 4.7 |
| KU812 (CML) | 13.0 ± 2.7 | 17.7 ± 2.4 | 21.6 ± 5.7 | 20.5 ± 2.4 |
| Sum | 85.5 | 218.6 | 104.3 | 103.1 |
a
Based on three independent biological replicates.
*
Combinations that have been tested for toxicity against normal blood cells at doses corresponding to CML treatment (maximal synergy cutoff >10 in both CML cell lines).
**
Combinations that have been tested for toxicity against normal blood cells at doses corresponding to both ALL and CML treatment (maximal synergy cutoff >10 in both ALL/CML cell lines).